Clinical trials: Nonexudative Age-related Macular Degeneration
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Age-Related Macular Degeneration, Geographic Atrophy
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years.
- Trial name
- APENNINES (NCT06351657)
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Geographic Atrophy of the Macula, Macular Degeneration
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
- Trial name
- SIGLEC (NCT05839041)
- Testing
- AVD-104, Avacincaptad
- Where
- 56 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aviceda Therapeutics, Inc.
Age-Related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Transpalpebral Microcurrent Stimulation for the Improvement of Visual Acuity in Patients With Macular Degeneration
The goal of this clinical trial is to evaluate the effectiveness of transpalpebral microcurrent stimulation as a therapy for dry age-related macular degeneration.
- Trial name
- NCT05703867
- Testing
- Active microcurrent therapy
- Volunteers
- 404 people
- Sponsor
- Jarding, John, OD
Dry Age-related Macular Degeneration
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- CORD-IV (NCT05706896)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Age Related Macular Degeneration, Cognition Disorders
The Zeaxanthin and Visual Function Study
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
- Trial name
- ZVF (NCT00564902)
- Testing
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Chrysantis, Inc.
Macular Degeneration Advanced, Macular Degeneration, Senile
Visual Rehabilitation Through Acoustic Biofeedback With Retimax Vision Trainer in Patients With Advanced Age-related Macular Degeneration
At present there are no real therapies able to improve visual performance in patients with age-related macular degeneration, atrophic type.
- Conditions
- Macular Degeneration Advanced, Macular Degeneration, Senile, Macular Degeneration, Dry, Macular Scar
- Trial name
- NCT04084587
- Testing
- Retimax Vision Trainer
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- University of Modena and Reggio Emilia
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
- Conditions
- Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
- Trial name
- i-SIGHT2 (NCT06662162)
- Testing
- i-Lumen AMD
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- i-Lumen Scientific AUS PTY LTD
Age-Related Macular Degeneration
Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration
The macular pigment (MP) in humans consists of the yellow, blue-absorbing carotenoids lutein and zeaxanthin. The highest concentrations of lutein and zeaxanthin are found in the fovea.
- Trial name
- NCT00879671
- Testing
- lutamax (leutein)
- Where
- Austria
- Volunteers
- 126 people
- Sponsor
- Medical University of Vienna
Age-related Macular Degeneration
Evaluate the Quality of Life of Patients With AMD
Age-related macular degeneration (AMD) is a major cause of deep visual acuity loss. Because of progressive deterioration of the macula, patients with AMD complain about progressive visual problems that can impair their quality of…
- Trial name
- QUASAR (NCT03242083)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Nonexudative Age-related Macular Degeneration
Directional Spread in Geographic Atrophy
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. In the late stages of the disease, neovascular changes or the development of geographic atrophy (GA) may induce severe…
- Trial name
- DSGA (NCT02051998)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University Hospital, Bonn
Nonexudative Age Related Macular Degeneration
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- NCT01601483
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MacuCLEAR, Inc.
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
- Trial name
- i-SIGHT (NCT05447650)
- Testing
- i-Lumen(TM) AMD
- Where
- 10 sites in United States
- Volunteers
- 95 people
- Sponsor
- i-Lumen Scientific, Inc.
Macular Degeneration
Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
Purpose: To determine drusen morphology (volume and area) changes in nonexudative age-related macular degeneration (AMD) after one year of oral supplementation with AREDS-like formulation.
- Trial name
- NCT02264938
- Testing
- Antioxidant
- Volunteers
- 35 people
- Sponsor
- Germans Trias i Pujol Hospital
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
Nonexudative Age-related Macular Degeneration
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.
- Trial name
- NCT01922128
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MacuCLEAR, Inc.
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration.
- Trial name
- NCT00447954
- Testing
- High Dose NT-501 implant, Low Dose NT-501 implant
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Neurotech Pharmaceuticals
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Age-related Macular Degeneration
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).
- Trial name
- PREVENT (NCT02140151)
- Testing
- Ranibizumab 0.5mg
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Southern California Desert Retina Consultants, MC
Nonexudative Age-related Macular Degeneration
Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration
The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on patients with dry Age Related Macular Degeneration (AMD).
- Trial name
- TORPA (NCT00940407)
- Testing
- Photobiomodulation (Gentlewaves, Warp 10)
- Where
- 2 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Merry, Graham, M.D.